EU label extension for Roche's RoActemra
This article was originally published in Scrip
Executive Summary
Roche's first-in-class interleukin-6 (IL-6) inhibitor RoActemra (tocilizumab) has been granted a label extension in the EU to include the reduction of the rate of progression of joint damage and improve physical function in patients with rheumatoid arthritis (RA), when given in combination with methotrexate.